SG10201709670XA - Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitor - Google Patents

Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitor

Info

Publication number: SG10201709670XA
Authority: SG; Singapore
Prior art keywords: administering; inhibitor; methods; specific immunotherapy; treating allergy
Prior art date: 2013-06-04

Application number

SG10201709670XA

Inventor

Neil Stahl

Jamie M Orengo

Andrew J Murphy

Namita Gandhi

Neil Graham

Original Assignee

Regeneron Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-06-04

Filing date

2014-06-03

Publication date

2018-01-30

2014-06-03 Application filed by Regeneron Pharma filed Critical Regeneron Pharma

2018-01-30 Publication of SG10201709670XA publication Critical patent/SG10201709670XA/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Microbiology (AREA)
Mycology (AREA)
Pulmonology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Endocrinology (AREA)

SG10201709670XA 2013-06-04 2014-06-03 Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitor SG10201709670XA (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201361830919P	2013-06-04	2013-06-04

Publications (1)

Publication Number	Publication Date
SG10201709670XA true SG10201709670XA (en)	2018-01-30

Family

ID=51023185

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
SG10201709670XA SG10201709670XA (en)	2013-06-04	2014-06-03	Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitor
SG11201509044QA SG11201509044QA (en)	2013-06-04	2014-06-03	Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitor
SG10201913835XA SG10201913835XA (en)	2013-06-04	2014-06-03	Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitor

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
SG11201509044QA SG11201509044QA (en)	2013-06-04	2014-06-03	Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitor
SG10201913835XA SG10201913835XA (en)	2013-06-04	2014-06-03	Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitor

Country Status (26)

Country	Link
US (5)	US10392439B2 (en)
EP (2)	EP3617233A1 (en)
JP (5)	JP6499167B2 (en)
KR (3)	KR102492826B1 (en)
CN (3)	CN105377894A (en)
AU (2)	AU2014275094C1 (en)
CA (1)	CA2914203C (en)
CY (1)	CY1124095T1 (en)
DK (1)	DK3004166T3 (en)
ES (1)	ES2767080T3 (en)
HK (1)	HK1216898A1 (en)
HR (1)	HRP20200185T1 (en)
HU (1)	HUE048655T2 (en)
IL (3)	IL273678B2 (en)
LT (1)	LT3004166T (en)
MX (2)	MX2015016473A (en)
NZ (1)	NZ630183A (en)
PL (1)	PL3004166T3 (en)
PT (1)	PT3004166T (en)
RS (1)	RS59883B1 (en)
RU (1)	RU2679920C2 (en)
SG (3)	SG10201709670XA (en)
SI (1)	SI3004166T1 (en)
TW (3)	TWI755763B (en)
WO (1)	WO2014197470A1 (en)
ZA (1)	ZA201508174B (en)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7608693B2 (en) *	2006-10-02	2009-10-27	Regeneron Pharmaceuticals, Inc.	High affinity human antibodies to human IL-4 receptor
EP3470432B1 (en)	2012-08-21	2021-10-06	Sanofi Biotechnology	Methods for treating or preventing asthma by administering an il-4r antagonist
TWI755763B (en)	2013-06-04	2022-02-21	美商再生元醫藥公司	Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitor
SG11201509625PA (en)	2013-06-21	2015-12-30	Sanofi Biotechnology	Methods for treating nasal polyposis by administering an il-4r antagonist
TWI682781B (en)	2013-07-11	2020-01-21	美商再生元醫藥公司	Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor
KR102695088B1 (en)	2014-02-28	2024-08-16	리제너론 파아마슈티컬스, 인크.	Methods for treating skin infection by administering an il-4r antagonist
TW201628649A (en)	2014-10-09	2016-08-16	再生元醫藥公司	Process for reducing subvisible particles in a pharmaceutical formulation
RU2734490C2 (en)	2014-11-14	2020-10-19	Санофи Байотекнолоджи	Methods of treating chronic sinusitis with nasal polyps by administering il-4r antagonist
US10858437B2 (en) *	2015-04-02	2020-12-08	Intervet, Inc.	Antibodies to canine interleukin-4 receptor alpha
US11091556B2 (en)	2015-12-18	2021-08-17	Intervet Inc.	Caninized human antibodies to human IL-4R alpha
JP7008020B2 (en) *	2015-12-18	2022-01-25	インターベットインターナショナルベー．フェー．	Canine humanized antibodies against human and canine IL-4R alpha
CA3014202A1 (en)	2016-02-19	2017-08-24	Regeneron Pharmaceuticals, Inc.	Methods for enhancing efficacy of a vaccine by administering an il-4r antagonist
CN109641050A (en)	2016-08-16	2019-04-16	里珍纳龙药品有限公司	Method for being quantified to the individual antibody in mixture
MX2019002344A (en) *	2016-09-01	2019-09-06	Regeneron Pharma	Methods for preventing or treating allergy by administering an il-4r antagonist.
CN109716138B (en)	2016-09-16	2023-10-03	武田药品工业株式会社	Protein biomarkers for contact activation system related diseases
WO2018057776A1 (en)	2016-09-22	2018-03-29	Regeneron Pharmaceuticals, Inc.	Methods for treating severe atopic dermatitis by administering an il-4r inhibitor
IL295211B2 (en)	2016-10-25	2024-09-01	Regeneron Pharma	Methods and systems for chromatography dataanalysis
TWI784988B (en)	2016-12-01	2022-12-01	美商再生元醫藥公司	Methods of treating inflammatory conditions
WO2019028367A1 (en)	2017-08-04	2019-02-07	Regeneron Pharmaceuticals, Inc.	Methods for treating active eosinophilic esophagitis
WO2019060062A1 (en)	2017-09-19	2019-03-28	Regeneron Pharmaceuticals Inc.	Methods of reducing particle formation and compositions formed thereby
HUE064655T2 (en)	2017-10-30	2024-04-28	Sanofi Biotechnology	Il-4r antagonist for use in a method for treating or preventing asthma
US11460452B2 (en)	2017-12-13	2022-10-04	Regeneron Pharmaceuticals, Inc.	Devices and systems for chromatography column bed support management and related methods
KR102652133B1 (en) *	2018-02-01	2024-03-29	베이징 카윈 테크놀로지 쉐어-홀딩 컴퍼니 리미티드	IL-4Rα antibody and its uses
CN108373505B (en) *	2018-04-20	2019-08-20	北京智仁美博生物科技有限公司	Anti- IL-4R antibody and application thereof
US20210054085A1 (en) *	2018-04-25	2021-02-25	Kiniksa Pharmaceuticals, Ltd.	Treatment of skin diseases or disorders by delivery of anti-osmrb antibody
TWI814812B (en)	2018-05-02	2023-09-11	美商里珍納龍藥品有限公司	Methods for evaluating suitability of a biochemical filter
SG11202009371WA (en)	2018-05-13	2020-10-29	Regeneron Pharma	Methods for treating atopic dermatitis by administering an il-4r inhibitor
CN112638931A (en)	2018-07-02	2021-04-09	里珍纳龙药品有限公司	Use of multiple hydrophobic interaction chromatography in the preparation of polypeptides from mixtures
JP2021531245A (en) *	2018-07-10	2021-11-18	リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc.	Modified bond molecules that minimize existing interactions
US20220049002A1 (en) *	2018-09-14	2022-02-17	Kindred Biosciences, Inc.	Anti-IL4 Receptor Antibodies for Veterinary Use
US20210403580A1 (en) *	2018-11-09	2021-12-30	Ajou University Industry-Academic Cooperation Foundation	Human antibody having high affinity to human il-4 receptor alpha, and use thereof
CN110746507B (en) *	2018-12-25	2020-06-26	江苏荃信生物医药有限公司	human interleukin 4 receptor α monoclonal antibody and its application
CN111647082B (en) *	2018-12-27	2023-02-17	中山康方生物医药有限公司	Antibodies against human IL-4RA and uses thereof
RU2700788C1 (en) *	2019-01-17	2019-09-23	Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства России (ФГБУ "ГНЦ Институт иммунологии" ФМБА России)	Method for assessment of efficiency of allergen-specific immunotherapy in allergic rhinitis
US11964016B2 (en) *	2019-03-21	2024-04-23	Regeneron Pharmaceuticals, Inc.	Combination of IL-4/IL-13 pathway inhibitors and plasma cell ablation for treating allergy
CA3147113A1 (en)	2019-08-05	2021-02-11	Regeneron Pharmaceuticals, Inc.	Methods for treating atopic dermatitis by administering an il-4r antagonist
SG11202113312VA (en)	2019-08-05	2021-12-30	Regeneron Pharma	Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r antagonist
CN111825766B (en) *	2019-10-31	2021-05-11	上海洛启生物医药技术有限公司	anti-IL-4R single domain antibody and application thereof
EP3992974A1 (en)	2020-11-02	2022-05-04	Sanofi Biotechnology	Methods for treating digitally-identified il-4/il-13 related disorders
WO2021119028A1 (en)	2019-12-09	2021-06-17	Sanofi Biotechnology	Methods for treating digitally-identified il-4/il-13 related disorders
MX2022013034A (en)	2020-04-17	2022-11-09	Shanghaimabgeekbiotech Co Ltd	Antibody to human interleukin-4 receptor î, preparation method therefor and use thereof.
KR102468170B1 (en) *	2020-07-17	2022-11-17	(주)지아이이노베이션	FUSION PROTEIN COMPRISING EXTRACELLULAR DOMAIN OF IgE Fc RECEPTOR ALPHA SUBUNIT AND ANTI-IL-4 RECEPTOR ANTIBODY AND USE THEREOF
AU2022206434A1 (en) *	2021-01-08	2023-08-24	Regeneron Pharmaceuticals, Inc.	Methods for treating peanut allergy and enhancing peanut allergen-specific immunotherapy by administering an il-4r antagonist
CN115960236B (en) *	2023-01-05	2024-08-06	江苏荃信生物医药股份有限公司	ELISA analysis method for quantitatively detecting content of anti-human interleukin 4 receptor alpha monoclonal antibody in serum

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8808015D0 (en)	1988-04-06	1988-05-05	Ritter M A	Chemical compounds
AU643427B2 (en)	1988-10-31	1993-11-18	Immunex Corporation	Interleukin-4 receptors
BR9205967A (en)	1991-05-03	1994-07-26	Seragen Inc	Interleukin receptor-labeled molecules treatment of inflammatory arthritis
JP3315427B2 (en)	1992-03-05	2002-08-19	大日本除蟲菊株式会社	Dermatitis treatment
US5714146A (en)	1992-08-26	1998-02-03	Board Of Regents Of The University Of Washington	IL-4 bone therapy
EP0604693A1 (en)	1992-12-29	1994-07-06	Schering-Plough	Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same
ZA946875B (en)	1993-09-07	1995-07-06	Smithkline Beecham Corp	Recombinant il4 antibodies useful in treatment of il4 mediated disorders
US6598603B1 (en)	1997-12-31	2003-07-29	Astra Aktiebolag	Method for treating respiratory diseases
CA2343052A1 (en)	1998-09-18	2000-03-30	Dynavax Technologies Corporation	Methods of treating ige-associated disorders and compositions for use therein
ATE551363T1 (en)	2000-05-26	2012-04-15	Immunex Corp	USE OF ANTIBODIES TO INTERLEUKIN-4 RECEPTOR AND COMPOSITIONS THEREOF
US7879328B2 (en)	2000-06-16	2011-02-01	Human Genome Sciences, Inc.	Antibodies that immunospecifically bind to B lymphocyte stimulator
ATE372764T1 (en)	2000-07-26	2007-09-15	Hououdou Co Ltd	ANTIPRURITIC COMPOSITIONS AND COMPOSITIONS PROMOTING WOUND HEALING
US20030103938A1 (en)	2001-05-09	2003-06-05	Alk-Abello A/S	Pharmaceutical compositions for preventing or treating Th1 and Th2 cell related diseases by modulating the Th1/Th2 ratio
JP2004529180A (en)	2001-05-11	2004-09-24	ノバルティスアクチエンゲゼルシャフト	Compositions for use in treating IgE-related disorders
DE60233519D1 (en)	2001-05-23	2009-10-08	Duotol Ab	SUPPRESSION OF ALLERGIC REACTIONS THROUGH TRANSCUTANEA ADMINISTRATION OF ANYTHING TOGETHER OR MERGED WITH TOXIN UNITS OR THEIR FRAGMENTS
EP2990394A1 (en)	2001-11-30	2016-03-02	Biogen MA Inc.	Antibodies against monocyte chemotactic proteins
CA2479927C (en)	2002-03-29	2013-03-12	Schering Corporation	Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same
WO2004047793A1 (en) *	2002-11-26	2004-06-10	Alk-Abelló A/S	Pharmaceutical allergen product
EP1592777A4 (en)	2003-02-01	2008-06-04	Tanox Inc	A method for generating high affinity antibodies
US7923209B2 (en)	2003-03-14	2011-04-12	Anergis, S.A.	Allergen peptide fragments and use thereof
EA011302B1 (en)	2003-11-07	2009-02-27	Иммунекс Корпорейшн	Antibodies that bind interleukin-4 receptor
EP1699825A2 (en)	2003-12-22	2006-09-13	Amgen, Inc.	Methods for identifying functional antibodies
CA2554596A1 (en)	2004-02-27	2005-09-15	Regeneron Pharmaceuticals, Inc.	Il-4/il-13 specific polypetides and therapeutic uses thereof
US20090098142A1 (en)	2004-06-09	2009-04-16	Kasaian Marion T	Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
TWI307630B (en)	2004-07-01	2009-03-21	Glaxo Group Ltd	Immunoglobulins
JP5234445B2 (en)	2004-10-05	2013-07-10	源一郎杣	Drug
WO2006083390A2 (en)	2004-12-07	2006-08-10	Children's Hospital Medical Center	Eotaxin-3 in eosinophilic esophagitis
TWI306862B (en)	2005-01-03	2009-03-01	Hoffmann La Roche	Antibodies against il-13 receptor alpha 1 and uses thereof
US8324192B2 (en)	2005-11-12	2012-12-04	The Regents Of The University Of California	Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8679545B2 (en)	2005-11-12	2014-03-25	The Regents Of The University Of California	Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
JP4221018B2 (en)	2006-08-31	2009-02-12	トヨタ自動車株式会社	Head protection airbag device
PL2769992T3 (en)	2006-10-02	2021-08-02	Regeneron Pharmaceuticals, Inc.	High affinity human antibodies to human IL-4 receptor
US7608693B2 (en) *	2006-10-02	2009-10-27	Regeneron Pharmaceuticals, Inc.	High affinity human antibodies to human IL-4 receptor
MX2009010092A (en)	2007-03-22	2010-02-09	Genentech Inc	Apoptotic anti- ige antibodies binding the membrane-bound ige.
EP2022507A1 (en)	2007-08-07	2009-02-11	Universität Hamburg	Antibody compositions specific for lgE, lgG4 and lgA epitopes as tools for the design of hypoallergenic molecules for specific immunotherapy
WO2009061819A1 (en)	2007-11-05	2009-05-14	The Regents Of The University Of Colorado	Minimally-invasive measurement of esophageal inflammation
US8092804B2 (en)	2007-12-21	2012-01-10	Medimmune Limited	Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
DE202008006598U1 (en)	2008-04-11	2008-10-02	Alk-Abelló A/S	Allergy vaccine formulation for mucosal administration
US20090264392A1 (en)	2008-04-21	2009-10-22	Meritage Pharma, Inc.	Treating eosinophilic esophagitis
US20110301046A1 (en)	2008-12-01	2011-12-08	Children's Hospital Medical Center	Methods of Determining Efficacy of Glucocorticoid Treatment of Eosinophilic Esophagitis
US20120088814A1 (en)	2009-03-31	2012-04-12	Isis Pharmaceuticals, Inc.	Methods of modulating an immune response to a viral infection
US8497528B2 (en)	2010-05-06	2013-07-30	Taiwan Semiconductor Manufacturing Company, Ltd.	Method for fabricating a strained structure
EP2475382B1 (en)	2009-09-07	2015-01-14	DBV Technologies	Method of treating eosinophilic esophagitis
US8993347B2 (en)	2009-12-17	2015-03-31	Cornell University	Methods for detecting antibodies in mucosal samples and device for sampling mucosal material
US20120164080A1 (en)	2010-06-24	2012-06-28	Meritage Pharma, Inc.	Methods of treatment for esophageal inflammation
CA2813587C (en)	2010-10-06	2019-01-15	Regeneron Pharmaceuticals, Inc.	Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
RU2453303C1 (en)	2010-12-23	2012-06-20	Общество с ограниченной ответственностью "ЦитоНИР" (ООО "ЦитоНИР")	Pharmaceutical composition for atopic dermatitis
US20130324435A1 (en)	2011-01-06	2013-12-05	Children's Hospital Medical Center	Esophageal cytokine expression profiles in eosinophilic esophagitis
US20130052190A1 (en)	2011-02-22	2013-02-28	Oxagen Limited	CRTH2 Antagonists for Treatment of Eosinophilic Diseases and Conditions
AU2012272858B2 (en)	2011-06-21	2017-03-09	Children's Hospital Medical Center	Diagnostic methods for eosinophilic esophagitis
EP2763683A1 (en)	2011-10-06	2014-08-13	N.V. Nutricia	Treatment of eosinophilic esophagitis
AU2012351342A1 (en)	2011-12-16	2014-07-24	Atopix Therapeutics Limited	Combination of CRTH2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
WO2013155010A1 (en)	2012-04-09	2013-10-17	Children's Hospital Medical Center	Non-invasive biomarkers for eosinophilic esophagitis
EP3470432B1 (en)	2012-08-21	2021-10-06	Sanofi Biotechnology	Methods for treating or preventing asthma by administering an il-4r antagonist
EP3354663A1 (en)	2012-09-07	2018-08-01	Regeneron Pharmaceuticals, Inc.	Methods for treating atopic dermatitis by administering an il-4r antagonist
US10132809B2 (en)	2012-10-10	2018-11-20	Rhote Island Hospital	Differential expression of protein markers for the diagnosis and treatment of eosinophilic esophagitis
ES2667420T3 (en)	2013-02-05	2018-05-10	Engmab Sàrl	Bispecific antibodies against cd3epsilon and bcma
TWI755763B (en)	2013-06-04	2022-02-21	美商再生元醫藥公司	Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitor
SG11201509625PA (en)	2013-06-21	2015-12-30	Sanofi Biotechnology	Methods for treating nasal polyposis by administering an il-4r antagonist
TWI682781B (en)	2013-07-11	2020-01-21	美商再生元醫藥公司	Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor
IL315136A (en)	2014-02-21	2024-10-01	Sanofi Biotechnology	Methods for treating or preventing asthma by administering an il-4rantagonist
KR102695088B1 (en)	2014-02-28	2024-08-16	리제너론 파아마슈티컬스, 인크.	Methods for treating skin infection by administering an il-4r antagonist
RU2734490C2 (en)	2014-11-14	2020-10-19	Санофи Байотекнолоджи	Methods of treating chronic sinusitis with nasal polyps by administering il-4r antagonist
CA3014202A1 (en)	2016-02-19	2017-08-24	Regeneron Pharmaceuticals, Inc.	Methods for enhancing efficacy of a vaccine by administering an il-4r antagonist
TWI777515B (en)	2016-08-18	2022-09-11	美商愛戴爾製藥股份有限公司	Methods of treating eosinophilic esophagitis
MX2019002344A (en)	2016-09-01	2019-09-06	Regeneron Pharma	Methods for preventing or treating allergy by administering an il-4r antagonist.
WO2018057776A1 (en)	2016-09-22	2018-03-29	Regeneron Pharmaceuticals, Inc.	Methods for treating severe atopic dermatitis by administering an il-4r inhibitor
AU2017332732B2 (en)	2016-09-22	2024-03-14	Regeneron Pharmaceuticals, Inc.	Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor
CA3052779A1 (en)	2017-02-17	2018-08-23	Fred Hutchinson Cancer Research Center	Combination therapies for treatment of bcma-related cancers and autoimmune disorders
EP3615068A1 (en)	2017-04-28	2020-03-04	Novartis AG	Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
WO2019028367A1 (en)	2017-08-04	2019-02-07	Regeneron Pharmaceuticals, Inc.	Methods for treating active eosinophilic esophagitis
HUE064655T2 (en)	2017-10-30	2024-04-28	Sanofi Biotechnology	Il-4r antagonist for use in a method for treating or preventing asthma
SG11202009371WA (en)	2018-05-13	2020-10-29	Regeneron Pharma	Methods for treating atopic dermatitis by administering an il-4r inhibitor
US11964016B2 (en)	2019-03-21	2024-04-23	Regeneron Pharmaceuticals, Inc.	Combination of IL-4/IL-13 pathway inhibitors and plasma cell ablation for treating allergy
CA3147113A1 (en)	2019-08-05	2021-02-11	Regeneron Pharmaceuticals, Inc.	Methods for treating atopic dermatitis by administering an il-4r antagonist
SG11202113312VA (en)	2019-08-05	2021-12-30	Regeneron Pharma	Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r antagonist
WO2021119028A1 (en)	2019-12-09	2021-06-17	Sanofi Biotechnology	Methods for treating digitally-identified il-4/il-13 related disorders
CN115768516A (en)	2020-05-22	2023-03-07	瑞泽恩制药公司	Methods of treating eosinophilic esophagitis by administering an inhibitor of IL-4R

2014
- 2014-05-30 TW TW109120861A patent/TWI755763B/en active
- 2014-05-30 TW TW107126334A patent/TWI697334B/en active
- 2014-05-30 TW TW103118916A patent/TWI633891B/en active
- 2014-06-03 SI SI201431427T patent/SI3004166T1/en unknown
- 2014-06-03 DK DK14733922.0T patent/DK3004166T3/en active
- 2014-06-03 KR KR1020227001662A patent/KR102492826B1/en active IP Right Grant
- 2014-06-03 US US14/294,544 patent/US10392439B2/en active Active
- 2014-06-03 EP EP19202527.8A patent/EP3617233A1/en active Pending
- 2014-06-03 CN CN201480032190.3A patent/CN105377894A/en active Pending
- 2014-06-03 JP JP2016518408A patent/JP6499167B2/en active Active
- 2014-06-03 RU RU2015156628A patent/RU2679920C2/en active
- 2014-06-03 CN CN202410184683.4A patent/CN117982639A/en active Pending
- 2014-06-03 ES ES14733922T patent/ES2767080T3/en active Active
- 2014-06-03 KR KR1020157034008A patent/KR102355114B1/en active Application Filing
- 2014-06-03 SG SG10201709670XA patent/SG10201709670XA/en unknown
- 2014-06-03 LT LTEP14733922.0T patent/LT3004166T/en unknown
- 2014-06-03 IL IL273678A patent/IL273678B2/en unknown
- 2014-06-03 KR KR1020237002686A patent/KR102580468B1/en active IP Right Grant
- 2014-06-03 MX MX2015016473A patent/MX2015016473A/en unknown
- 2014-06-03 CA CA2914203A patent/CA2914203C/en active Active
- 2014-06-03 IL IL312710A patent/IL312710A/en unknown
- 2014-06-03 HU HUE14733922A patent/HUE048655T2/en unknown
- 2014-06-03 EP EP14733922.0A patent/EP3004166B1/en active Active
- 2014-06-03 CN CN202410184651.4A patent/CN118001391A/en active Pending
- 2014-06-03 AU AU2014275094A patent/AU2014275094C1/en active Active
- 2014-06-03 WO PCT/US2014/040695 patent/WO2014197470A1/en active Application Filing
- 2014-06-03 RS RS20200093A patent/RS59883B1/en unknown
- 2014-06-03 PL PL14733922T patent/PL3004166T3/en unknown
- 2014-06-03 NZ NZ630183A patent/NZ630183A/en unknown
- 2014-06-03 SG SG11201509044QA patent/SG11201509044QA/en unknown
- 2014-06-03 SG SG10201913835XA patent/SG10201913835XA/en unknown
- 2014-06-03 PT PT147339220T patent/PT3004166T/en unknown
2015
- 2015-11-04 IL IL242456A patent/IL242456B/en active IP Right Grant
- 2015-11-04 ZA ZA2015/08174A patent/ZA201508174B/en unknown
- 2015-11-30 MX MX2021002173A patent/MX2021002173A/en unknown
2016
- 2016-04-25 HK HK16104712.1A patent/HK1216898A1/en unknown
2017
- 2017-12-14 US US15/842,868 patent/US10676530B2/en active Active
- 2017-12-14 US US15/842,865 patent/US10669341B2/en active Active
2019
- 2019-03-13 JP JP2019045324A patent/JP6754857B2/en active Active
- 2019-06-27 AU AU2019204577A patent/AU2019204577B2/en active Active
2020
- 2020-02-05 HR HRP20200185TT patent/HRP20200185T1/en unknown
- 2020-02-10 CY CY20201100122T patent/CY1124095T1/en unknown
- 2020-04-24 US US16/858,488 patent/US11485788B2/en active Active
- 2020-08-21 JP JP2020139935A patent/JP7061163B2/en active Active
2022
- 2022-04-14 JP JP2022066688A patent/JP7284313B2/en active Active
- 2022-09-23 US US17/935,003 patent/US20230159647A1/en active Pending
2023
- 2023-05-17 JP JP2023081214A patent/JP7575526B2/en active Active

Also Published As

Publication number	Publication date
US10392439B2 (en)	2019-08-27
RS59883B1 (en)	2020-03-31
KR20160014626A (en)	2016-02-11
IL273678B1 (en)	2024-06-01
PT3004166T (en)	2020-01-14
IL273678B2 (en)	2024-10-01
SG11201509044QA (en)	2015-12-30
KR102580468B1 (en)	2023-09-21
AU2014275094B2 (en)	2019-03-28
IL273678A (en)	2020-05-31
TW201519905A (en)	2015-06-01
TWI633891B (en)	2018-09-01
US11485788B2 (en)	2022-11-01
AU2021229250A1 (en)	2021-10-07
KR20220011810A (en)	2022-01-28
JP2023103389A (en)	2023-07-26
US20180094070A1 (en)	2018-04-05
US20230159647A1 (en)	2023-05-25
TWI755763B (en)	2022-02-21
SG10201913835XA (en)	2020-03-30
US20140356372A1 (en)	2014-12-04
EP3617233A1 (en)	2020-03-04
JP7061163B2 (en)	2022-04-27
IL312710A (en)	2024-07-01
KR20230017923A (en)	2023-02-06
KR102355114B1 (en)	2022-01-27
JP2019112440A (en)	2019-07-11
CN105377894A (en)	2016-03-02
HK1216898A1 (en)	2016-12-09
US10676530B2 (en)	2020-06-09
JP6754857B2 (en)	2020-09-16
LT3004166T (en)	2019-12-27
EP3004166A1 (en)	2016-04-13
CA2914203C (en)	2024-04-16
CY1124095T1 (en)	2022-03-24
AU2014275094C1 (en)	2019-10-10
RU2015156628A (en)	2017-07-14
SI3004166T1 (en)	2020-02-28
JP6499167B2 (en)	2019-04-10
EP3004166B1 (en)	2019-11-20
MX2021002173A (en)	2021-04-28
AU2019204577A1 (en)	2019-07-18
AU2014275094A1 (en)	2015-12-17
CN117982639A (en)	2024-05-07
AU2019204577B2 (en)	2021-06-24
KR102492826B1 (en)	2023-01-30
TW202038999A (en)	2020-11-01
ES2767080T3 (en)	2020-06-16
NZ630183A (en)	2018-10-26
RU2679920C2 (en)	2019-02-14
US20180094069A1 (en)	2018-04-05
CN118001391A (en)	2024-05-10
HRP20200185T1 (en)	2020-05-01
CA2914203A1 (en)	2014-12-11
WO2014197470A1 (en)	2014-12-11
IL242456B (en)	2020-04-30
MX2015016473A (en)	2016-03-03
ZA201508174B (en)	2017-09-27
RU2015156628A3 (en)	2018-05-30
JP7284313B2 (en)	2023-05-30
TW201906630A (en)	2019-02-16
JP2022101613A (en)	2022-07-06
RU2019103601A (en)	2019-03-12
TWI697334B (en)	2020-07-01
US20200299393A1 (en)	2020-09-24
PL3004166T3 (en)	2020-06-01
DK3004166T3 (en)	2020-01-06
HUE048655T2 (en)	2020-08-28
US10669341B2 (en)	2020-06-02
JP7575526B2 (en)	2024-10-29
JP2016521713A (en)	2016-07-25
JP2020193218A (en)	2020-12-03

Publication	Publication Date	Title
IL273678A (en)	2020-05-31	Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitor
IL274464A (en)	2020-06-30	Compositions and methods for detecting rare sequence variants
HK1224140A1 (en)	2017-08-18	Inhibitors of transcription factors and uses thereof
HK1219947A1 (en)	2017-04-21	Carm1 inhibitors and uses thereof carm1
ZA201504902B (en)	2016-07-27	Bcl-2bcl-xl inhibitors and therapeutic methods using the same
PL3637254T3 (en)	2023-07-31	Portable device and method for restricting use of portable device
EP3045892A4 (en)	2016-11-02	Gas analysis device and gas analysis method
EP2967547A4 (en)	2016-10-12	Anastomotic device and method
EP2972313A4 (en)	2016-11-30	Ported parallel plate flow chamber and methods for use thereof
HK1223112A1 (en)	2017-07-21	Anti-tnf-alpha/cxcl10 double-targeting antibody and use thereof -tnf-/cxcl10
HK1224307A1 (en)	2017-08-18	Protoxin-ii variants and methods of use -ii
EP2959712A4 (en)	2016-11-09	Method and system for identifying exceptions of people behavior
SG2013093067A (en)	2015-07-30	Method and system for verification of presence
PL3010620T3 (en)	2020-11-02	Filter device and discharge method
EP2964225A4 (en)	2016-01-27	CaMKII INHIBITORS AND USES THEREOF
GB201604534D0 (en)	2016-05-04	Nucleic-acid-sequence determination device and nucleic-acid-sequence determination method
HK1216754A1 (en)	2016-12-02	Anti-rankl antibodies and methods of use -rankl
EP3065038A4 (en)	2016-10-19	Method for presenting terminal device and terminal device
EP3022205A4 (en)	2016-11-23	Novel phosphodiesterase inhibitors and uses thereof
SG11201600347UA (en)	2016-02-26	Gas purge device and gas purge method
GB201307317D0 (en)	2013-05-29	Valve System and Methods of Operation Thereof
PT2769654T (en)	2021-01-08	Gas grill and method thereof
EP2972012A4 (en)	2016-11-02	Compressor device and method
GB201313068D0 (en)	2013-09-04	Apparatuses and methods for ananlysing charged species
GB201315673D0 (en)	2013-10-16	Vending apparatus and methods of vending